Prostate Cancer Clinical Trials in Illinois

Showing 181-200 of 282 trials

Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

NCT02685267

This is a prospective randomized phase II clinical trial where patients who are receiving enzalutamide in the pre-chemotherapy space are randomized upon objective progression (radiographic and/or clinical per PCWG2 criteria) to docetaxel/prednisone alone or the same combination plus enzalutamide. The primary aim is to evaluate whether continuing enzalutamide in combination with docetaxel in patients who failed or progressed while on enzalutamide would increase progression-free survival (PFS) by 4 months. The secondary end points are PSA responses, percent of patients alive at 1 and 2 years, decline in circulating tumor cells (CTCs), and quality of life (QOL) using validated scales.

Prostate Cancer

Prostate Cancer Clinical Trials Consortium9 participantsStarted Feb 2016

Chicago, Illinois, United States • Decatur, Illinois, United States • Evanston, Illinois, United States +2 more locations

COMPLETED117 miles

A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

NCT04015102

This prospective registry will evaluate the feasibility and impact of implementing standard cancer family history review and guideline-aligned genetic testing for men diagnosed with Prostate Cancer in community urology practices nationwide.

Prostate Cancer

Myriad Genetic Laboratories, Inc.255 participantsStarted Mar 2019

Little Rock, Arkansas, United States • Fresno, California, United States • Merrillville, Indiana, United States +7 more locations

Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

Prostate Cancer Trials in Other Cities

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

Other Conditions in Illinois